This clinical trial is focused on studying the treatment of complicated urinary tract infections (cUTI) and acute uncomplicated pyelonephritis (AP) in adults. These are types of infections that affect the urinary system, which includes the kidneys, bladder, and the tubes that connect them. The study will compare the effectiveness and safety of two different treatment combinations: cefepime/nacubactam and aztreonam/nacubactam, against another treatment called imipenem/cilastatin. All these medications are given through an intravenous (IV) infusion, which means they are administered directly into a vein.
The purpose of the study is to evaluate how well these treatments work and how safe they are for patients with these infections. Participants in the study will receive one of the treatment combinations or a placebo, and their progress will be monitored over a period of time. The study will involve regular visits to the clinic for check-ups and assessments to see how the infection is responding to the treatment. The goal is to find out which treatment is most effective in curing the infection and preventing it from coming back.
Throughout the study, participants will be closely observed to ensure their safety and to monitor any side effects that may occur. The study aims to provide valuable information that could help improve the treatment of these types of infections in the future. By comparing the different treatment options, researchers hope to identify the best approach for managing cUTI and AP, ultimately leading to better outcomes for patients.
Bulgaria 
Czechia 
Estonia 
Latvia 
Lithuania 
Slovakia 
